The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Steering Committee About Us Newsletter Contact

Visit:

Steering Committee About Us Newsletter Contact

Subtypes Therapeutics Congresses Trials Expert Opinions

ESH Symposium

Lymphoma & CLL Subtypes

Lymphoma & CLL Therapeutics

View all the latest information in lymphoma and CLL, arranged by therapeutic class and intervention. Listed below are recently updated therapeutic classes.

CAR T-cell therapy

Cellular therapy

Kinase inhibitors

Chemotherapy

Immune modulators

Checkpoint inhibitors

Conjugated antibodies

Bispecific antibodies

Recently Added

Antibody therapy

LyMa-101 trial update: Obinutuzumab for the treatment of mantle cell lymphoma

Summary of the updated results from the phase II LyMA-101 trial evaluating obinutuzumab plus high-dose cytarabine for the...

Oct 22, 2020

| MCL

The prognostic value of PET scan in the treatment of DLBCL

A summary of two studies evaluating the outcomes of PET-guided treatment decisions in patients with limited-stage and advanced-stage DLBCL.

Oct 20, 2020

| DLBCL

Checkpoint inhibitors

Phase I trial of the triplet therapy ipilimumab, nivolumab, and brentuximab vedotin for patients with relapsed/refractory Hodgkin lymphoma

A summary of the results from a phase I clinical trial...

Oct 21, 2020

| cHL

Pembrolizumab receives FDA approval for extended indications in classical Hodgkin lymphoma

FDA extends indication for pembrolizumab as a monotherapy for adult and pediatric patients with cHL.

Oct 19, 2020

| cHL

CAR T-cell therapy

KTE-X19 receives CHMP positive opinion for the treatment of patients with R/R MCL

On October 16, 2020, brexucabtagene autoleucel received positive opinion from the EMA CHMP for the treatment of adult...

Oct 19, 2020

| MCL

Lymphodepletion optimization for CAR T-cell therapy

A summary of the talk by Elizabeth Budde at the eighth annual meeting of the SOHO regarding the optimization of lymphodepletion protocols.

Oct 15, 2020

| SOHO 2020

Kinase inhibitors

Lymphoma Hub Symposium | The value of BTK inhibitors for the treatment of patients with R/R CLL

A summary of the therapeutic value of BTK inhibitors in the R/R CLL setting and their journey into...

Oct 16, 2020

| ESH Symposium

Phase III CHRONOS-3 study evaluating copanlisib and rituximab combination meets primary endpoint

Phase III CHRONOS-3 study, evaluating copanlisib in combination with rituximab for relapsed iNHL, meets...

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Lymphoma & CLL Therapeutics

View all the latest information in lymphoma and CLL, arranged by therapeutic class and intervention. Listed below are recently updated therapeutic classes.

Recently Added

Antibody therapy

Oct 22, 2020

| MCL

Oct 20, 2020

| DLBCL

Checkpoint inhibitors

Oct 21, 2020

| cHL

Oct 19, 2020

| cHL

CAR T-cell therapy

Oct 19, 2020

| MCL

Oct 15, 2020

| SOHO 2020

Kinase inhibitors

Oct 16, 2020

| ESH Symposium

Oct 15, 2020

All Interventions